YOLFTbeta
05

Kyung Nam Pharm Co Ltd

053950 · KQ

1,482.00KRW-11.00 (-0.74%)

Price History

Full chart

Market Stats

Previous Close1,493.00
Open1,519.00
Day Range1,470.00 – 1,523.00
52-Week Range1,415.00 – 5,580.00
Volume29.52K
Market Cap31.17B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.03
50-Day Avg1,817.34
200-Day Avg2,726.56

About

Kyung Nam Pharm Co.,Ltd. manufactures pharmaceuticals. The company offers over-the-counter products, including antipyretics, analgesics, and antiphlogistics; medications for skin diseases and athlete's foot; pain relief patches/creams, antitussives, mucolytic agents, and expectorants; gastro protective agents/digestives; periodontal/gum disease drugs; medications for liver diseases; ear and nose solutions; nutritious tonics; circulatory drugs; and vitamins and minerals products. It also provides prescription-only medicines, such as pure kin solutions, plagensia inj., arobin inj., and galonic inj.; quasi drugs, such as vitamins and other drugs; health functional food products, including intestine health, weight loss, stress relieve, and vitamins and minerals; as well as other food products. Kyung Nam Pharm Co.,Ltd. was formerly known as HS Bio Pharm Co., Ltd. and changed its name to Kyung Nam Pharm Co.,Ltd. in May, 2010. Kyung Nam Pharm Co.,Ltd. was founded in 1957 and is headquartered in Uiryeong, South Korea with an additional office in Seoul, South Korea.

Company Details

Leadership

  • Ms. Eun HoeSr. Managing Director · b. 1960
  • Mr. Oh Chang HwanChief Exec. Officer

Financials

Income Statement

Currency: KRW2007-12-312008-12-312009-12-312010-12-312016-12-312017-12-312018-12-312019-12-312020-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue31.29B51.37B55.73B52.44B39.76B40.17B41.43B44.81B70.95B59.00B59.30B60.79B55.94B
Growth (%)-+64.18%+8.48%-5.90%-24.18%+1.04%+3.14%+8.14%+58.34%-16.84%+0.51%+2.51%-7.97%
Cost of Revenue14.13B19.46B27.42B28.41B22.32B23.06B24.76B27.96B42.47B42.61B40.01B43.57B40.80B
Gross Profit----17.44B17.11B16.68B16.84B28.47B16.39B19.30B17.23B15.15B
Gross Margin----43.87%42.59%40.25%37.59%40.13%27.79%32.54%28.33%27.07%
Operating Expense----15.23B13.82B18.94B21.78B26.29B19.79B22.88B17.47B16.88B
Operating Income-13.81B4.84B655.78M2.21B3.29B-2.27B-4.94B2.18B-3.39B-3.59B-242.82M-1.73B
Operating Margin-26.88%8.68%1.25%5.55%8.19%-5.47%-11.02%3.07%-5.75%-6.05%-0.40%-3.10%
EBITDA----------3.48B-4.08B1.24B-5.91B
EBITDA Margin----------5.90%-6.88%2.04%-10.56%
Net Income-993.60M--129.81M-3.48B3.72B-4.55B-5.49B-7.83B-21.00B10.08B-9.01B
Net Income Margin-1.93%--0.33%-8.66%8.98%-10.15%-7.73%-13.27%-35.41%16.58%-16.10%
R&D----------1.00M--
R&D as % of Total Revenue----------0.00%--
Interest Expense0000000001.95B1.65B1.98B1.06B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.31%2.79%3.26%1.89%

Balance Sheet

Currency: KRW2007-12-312008-12-312009-12-312010-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets46.40B65.05B91.51B89.20B-45.18B-53.16B74.46B126.66B138.27B166.61B166.58B155.63B
Total Liabilities31.55B43.50B62.41B67.22B-28.35B-24.24B13.27B69.29B44.50B76.78B51.36B47.33B
Total Equity9.69B14.75B22.98B16.15B-16.82B-28.91B61.19B57.36B93.77B79.36B115.22B108.30B
Cash15.55B12.95B20.91B11.17B-3.76B-8.41B23.93B22.73B42.99B25.96B50.81B6.25B
Total Debt-----5.00B--390.49M27.68B----
Net Debt-----------24.48B-29.02B

Cash Flow

Currency: KRW2007-12-312008-12-312009-12-312010-12-312016-12-312017-12-312018-12-312019-12-312020-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow148.79M--482.65M4.89B1.72B-1.75B-6.43B2.62B71.58M693.30M1.84B-1.68B
Investing Cash Flow-----1.21B356.17M-3.30B808.61M-50.07B----
Financing Cash Flow25.84B8.47B24.53B838.98M-1.59B2.70B4.92B21.13B46.31B----
Capital Expenditure3.99B3.71B8.61B10.89B1.11B1.05B526.76M1.32B45.58B2.92B4.18B1.67B1.26B
Free Cash Flow----------2.85B-3.48B171.88M-2.94B
Dividends Paid1.21M------------
FCF to OCF----------3976.94%-502.45%9.35%175.08%

Earnings

Report DateSep 30, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014May 13, 2015Aug 14, 2015Nov 13, 2015Feb 12, 2016May 13, 2016Aug 16, 2016Nov 14, 2016Feb 15, 2017May 15, 2017Aug 14, 2017Nov 14, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------------------------------------------
EPS Actual-1330.76-367.31899.36-99.99-2527.83107.8018.63-46.92-73.59-195.53-4538.10-403.48-812.2892.8925.0742.4439.3019.28100.0635.90-23.1326.22-108.4279.3110.725.89-62.0233.87-880.20-2910.67-354.69-383.034776.9011.05-119.94-137.18-687.43199.21236.53-707.61-806.06564.93504.40-1307.93-577.36-536.75132.0630.85-591.65-11.86-402.35-236.34-1665.38-121.421896.22-446.09-129.40-100.30161.76-299.19-338.54-45.08-199.78
Surprise---------------------------------------------------------------
Timing-----------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-----------------------------------

Key Statistics & Ratios

Market Cap31.17B
Enterprise Value18.68B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.62
Price / Book0.29
Revenue (TTM)70.10B
Gross Profit (TTM)28.40B
EBITDA3.41B
Profit Margin-5.16%
Operating Margin2.67%
Return on Equity-5.86%
Return on Assets1.17%
Shares Outstanding0
Shares Float11.89M
Beta-0.03
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20041×
691.30Dec 29, 2004
20031×
432.06Dec 29, 2003

Stock Splits

  • May 7, 20261:5
  • Sep 2, 20241753:1371
  • Jan 26, 2022827:731
  • Jan 2, 20141:5